Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy
Tania Zaglia, Giulia Milan, Aaron Ruhs, Mauro Franzoso, Enrico Bertaggia, Nicola Pianca, Andrea Carpi, Pierluigi Carullo, Paola Pesce, David Sacerdoti, Cristiano Sarais, Daniele Catalucci, Marcus Krüger, Marco Mongillo, Marco Sandri
Tania Zaglia, Giulia Milan, Aaron Ruhs, Mauro Franzoso, Enrico Bertaggia, Nicola Pianca, Andrea Carpi, Pierluigi Carullo, Paola Pesce, David Sacerdoti, Cristiano Sarais, Daniele Catalucci, Marcus Krüger, Marco Mongillo, Marco Sandri
View: Text | PDF
Research Article Cardiology

Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy

  • Text
  • PDF
Abstract

Cardiomyocyte proteostasis is mediated by the ubiquitin/proteasome system (UPS) and autophagy/lysosome system and is fundamental for cardiac adaptation to both physiologic (e.g., exercise) and pathologic (e.g., pressure overload) stresses. Both the UPS and autophagy/lysosome system exhibit reduced efficiency as a consequence of aging, and dysfunction in these systems is associated with cardiomyopathies. The muscle-specific ubiquitin ligase atrogin-1 targets signaling proteins involved in cardiac hypertrophy for degradation. Here, using atrogin-1 KO mice in combination with in vivo pulsed stable isotope labeling of amino acids in cell culture proteomics and biochemical and cellular analyses, we identified charged multivesicular body protein 2B (CHMP2B), which is part of an endosomal sorting complex (ESCRT) required for autophagy, as a target of atrogin-1–mediated degradation. Mice lacking atrogin-1 failed to degrade CHMP2B, resulting in autophagy impairment, intracellular protein aggregate accumulation, unfolded protein response activation, and subsequent cardiomyocyte apoptosis, all of which increased progressively with age. Cellular proteostasis alterations resulted in cardiomyopathy characterized by myocardial remodeling with interstitial fibrosis, with reduced diastolic function and arrhythmias. CHMP2B downregulation in atrogin-1 KO mice restored autophagy and decreased proteotoxicity, thereby preventing cell death. These data indicate that atrogin-1 promotes cardiomyocyte health through mediating the interplay between UPS and autophagy/lysosome system and its alteration promotes development of cardiomyopathies.

Authors

Tania Zaglia, Giulia Milan, Aaron Ruhs, Mauro Franzoso, Enrico Bertaggia, Nicola Pianca, Andrea Carpi, Pierluigi Carullo, Paola Pesce, David Sacerdoti, Cristiano Sarais, Daniele Catalucci, Marcus Krüger, Marco Mongillo, Marco Sandri

×

Figure 5

Atrogin-1 ablation leads to impairment in the autophagy flux.

Options: View larger image (or click on image) Download as PowerPoint
Atrogin-1 ablation leads to impairment in the autophagy flux.
(A and B) ...
(A and B) Western blotting on ventricular extracts from aged control, atrogin-1 KO, and starved control (starv) mice. The LC3-II/β-tubulin ratio was evaluated in control and atrogin-1 KO hearts. Error bars indicate SEM (*P < 0.01; n = 6 for each group). (C and D) Confocal immunofluorescence on ventricular cryosections from 9- and 16-month-old control and atrogin-1 KO mice costained with antibodies against sarcomeric actinin (α-actinin) and (C) p62 or (D) LC3, showing p62 and LC3 aggregates in both adult and aged atrogin-1 KO cardiomyocytes (arrows). Scale bar: 20 μm (inset in C); 25 μm (C, 9- and 16-month-old control and 9-month-old atrogin-1 KO, and D); 50 μm (C, 16-month-old atrogin-1 KO). (E) Confocal 3D reconstruction of a ventricular cardiomyocyte from an aged atrogin-1 KO mouse costained with antibodies against p62 and LC3. Scale bar: 20 μm (left image); 10 μm (right image). (F) Western blotting on ventricular extracts from 9- and 16-month-old control and atrogin-1 KO hearts, showing LAMP2 accumulation in atrogin-1 KO hearts. (G) Confocal immunofluorescence on ventricular cryosections from aged control and atrogin-1 KO mice costained with antibodies against LAMP2 and dystrophin. Scale bar: 50 μm. (H) Confocal 3D reconstruction of a ventricular cardiomyocyte from aged atrogin-1 KO mice costained with antibodies against LAMP2 and LC3. Scale bar: 30 μm; 5 μm (inset). (I) Western blotting on ventricular extracts from aged control and atrogin-1 KO mice treated either with DMSO or the lysosome inhibitor bafilomycin (BFL). The LC3-II/β-tubulin ratio was evaluated in DMSO- and BLF-treated control and atrogin-1 KO hearts. Error bars indicate SEM (**P < 0.01; n = 6 for each group).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts